Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide is a synthetic small molecule with the chemical formula C9H16N2O7. It has been studied primarily as an experimental ligand and inhibitor of glycogen phosphorylase, particularly the muscle isoform (PYGM). Glycogen phosphorylase is a key enzyme in glycogen catabolism, catalyzing the rate-limiting step in the breakdown of glycogen to glucose-1-phosphate, thus playing a central role in cellular and organismal glucose homeostasis. By binding to this enzyme, 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide can modulate its activity, making it of interest for research into metabolic regulation and potential therapeutic targeting of disorders involving glycogen metabolism[3][9][10]. There is no evidence that this compound has been developed or marketed as a pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide.